Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$47.62 USD

47.62
1,462,070

-1.35 (-2.76%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $47.70 +0.08 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Proteostasis Stock Surges on Positive Data From CF Studies

by Zacks Equity Research

Proteostasis (PTI) stock skyrockets on positive results from early and mid-stage studies on its cystic fibrosis pipeline candidates.

    Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma

    by Zacks Equity Research

    Merck (MRK) informs that the FDA grants a priority review to its supplemental biologics license application looking for its marketed drug Keytruda's label expansion for a rare lymphoma indication.

      Spark Therapeutics Stock Plunges on Hemophilia Therapy Data

      by Zacks Equity Research

      Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.

        Lilly Reports Mixed Results from Late-Stage Cyramza Study

        by Zacks Equity Research

        Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.

          Roche Reports Tecentriq/Avastin Lung Cancer Study Data

          by Zacks Equity Research

          Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.

            Revance's Neuromodulator Injection Positive in Phase III

            by Zacks Equity Research

            Revance (RVNC) releases positive top-line data from two pivotal phase III trials, evaluating RT002 for reducing wrinkles between the brows. The studies meet both primary and secondary endpoints.

              Here's Why Sarepta Stock is Up More Than 70% in 6 Months

              by Zacks Equity Research

              Sarepta's (SRPT) key product, Exondys 51, and lead pipeline candidate, golodirsen, have put up a good show in the past six months.

                AstraZeneca's COPD Drug Succeeds in Label Expansion Study

                by Zacks Equity Research

                AstraZeneca (AZN) releases positive top-line data from a phase IV study, evaluating label expansion of Tudorza for chronic obstructive pulmonary disease with cardiovascular risk factors.

                  Ironwood Succeeds in Diabetic Hypertension Phase II Study

                  by Zacks Equity Research

                  Ironwood Pharmaceuticals' (IRWD) pipeline candidate, IW-1973, reduces blood pressure and improves metabolic parameters in type II diabetes with hypertension patients in a phase IIa study.

                    Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug

                    by Zacks Equity Research

                    Pfizer (PFE) inks a deal to buy exclusive rights to develop and commercialize Basilea Pharmaceutica's anti-fungal treatment, Cresemba, in the Asia-Pacific region and China.

                      Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success

                      by Zacks Equity Research

                      Bristol-Myers' (BMY) phase III study evaluating Opdivo versus docetaxel was stopped earlier than expected as it met the primary endpoint.

                        Celldex Begins Phase I Trial on Cancer Candidate CDX-1140

                        by Zacks Equity Research

                        Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.

                          Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA

                          by Zacks Equity Research

                          Glaxo (GSK) and partner Medicines for Malaria Venture filed a new drug application (NDA) with the FDA for single-dose anti relapse medicine for malaria.

                            AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA

                            by Zacks Equity Research

                            AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.

                              Valeant Closes Senior Note Offering, Reprices Term Loan

                              by Zacks Equity Research

                              Valeant (VRX) offered new debt and restructured old debt. The company is making efforts to repay its huge level of debt.

                                Can Valeant (VRX) Turn Around on Rebuilding Initiatives?

                                by Zacks Equity Research

                                Valeant (VRX) has performed much better so far in 2017 compared to last year on the back of rebuilding initiatives.

                                  Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?

                                  by Zacks Equity Research

                                  Mallinckrodt plc (MNK)'s stock lost 55% in the year so far due to ongoing investigations and weakness in Acthar and Inomax.

                                    Roche Reports Positive Data From Tecentriq Combination Study

                                    by Zacks Equity Research

                                    Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin.

                                      Alnylam Starts Rolling NDA Submission for RNAi Candidate

                                      by Zacks Equity Research

                                      Alnylam (ALNY) has started rolling New Drug Application to the FDA for its RNAi candidate, patisiran.

                                        Incyte (INCY) Initiates Essential Thrombocythemia Trial

                                        by Zacks Equity Research

                                        Incyte (INCY) announced that the first patient has been treated in the essential thrombocythemia trial on ruxolitinib. A potential label expansion of the drug will boost sales.

                                          Valeant (VRX) Announces Pricing of Senior Secured Notes

                                          by Zacks Equity Research

                                          Valeant (VRX) prices its senior secured notes. The proceeds of the notes will be used to pay down its existing debt.

                                            Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test

                                            by Zacks Equity Research

                                            Roche's (RHHBY) diagnostic portfolio gets a further boost with FDA's clearance for Ventana tests.

                                              Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee

                                              by Zacks Equity Research

                                              Pacira (PCRX) announced that the FDA has asked for an Advisory Committee Meeting to review the supplemental New Drug Application for expanded indication of Exparel in the nerve block setting.

                                                Cardinal Health (CAH) to Divest Assets to Shanghai Pharma

                                                by Zacks Equity Research

                                                Cardinal Health (CAH) will streamline its Chinese operations by disposing pharmaceutical and medical products distribution business in China.

                                                  Shire Gets Positive CHMP Opinion for Hemophilia A Drug

                                                  by Zacks Equity Research

                                                  Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.